Target intelligence / Profile preview

Ephrin type-B receptor 1 (EPHB1)

Target
EPHB1
Molecular classification
Receptor tyrosine kinase, Receptor, Transmembrane protein
01

Overview

Ephrin type-B receptor 1 (EPHB1) is a member of the Eph family of receptor tyrosine kinases that serve as key mediators of cell-cell communication during development and in adult tissues[1][7]. EPHB1 binds to ephrin-B ligands on adjacent cells, initiating a unique form of contact-dependent bidirectional signaling: forward signaling through EPHB1 and reverse signaling through the ephrin ligands[1][9]. This receptor is crucial in axon guidance, particularly in the nervous system where it regulates retinal axon crossing and neural progenitor dynamics. Beyond the nervous system, EPHB1 participates in angiogenesis, cell migration, cell adhesion, and stem cell maintenance, and is implicated in cancer biology and progression[1][3][7]. EPHB1-mediated signaling activates several downstream pathways, including MAPK/ERK and JNK, affecting cell proliferation, polarity, and chemotaxis. Because of its involvement in developmental, neural, and oncogenic processes, EPHB1 and related receptors are being explored as therapeutic targets, particularly in oncology and regenerative medicine[1][4].

Other names
EphB1ELKEPHT2HEK6NETEK6hEK6EPH tyrosine kinase 2Eph-like kinase 6Neuronally-expressed EPH-related tyrosine kinaseTyrosine-protein kinase receptor EPH-2
02

Mechanism of action

Inhibition of kinase domain signaling (small molecules, e.g., kinase inhibitors); Blockade of ephrin ligand-receptor interaction (antibodies or fusion proteins); Induction of receptor internalization and degradation (antibody-drug conjugates, biologics)

03

Biological functions

Signal transductionAxon guidanceCell migrationCell adhesionChemotaxisProliferation of neural progenitorsDendritic spine and synapse formationAngiogenesisMaintenance of stem cell pools
04

Disease associations

CancerGliomaHematologic cancerOther neurodevelopmental and neurodegenerative disorders (inferred by function[1][7])
05

Safety considerations

Potential effects on neural development and synaptic function, given expression in nervous systemEffects on stem cell function and tissue repairPossible vascular side effects due to roles in angiogenesis
06

Interacting drugs

No clinically approved drugs specifically target EPHB1, but small-molecule inhibitors and antibodies against Eph receptors are in preclinical or early clinical development.

2 more in the full profile.

07

Biomarkers

EPHB1 expression as a predictive biomarker (primarily in research) for certain cancers (e.g., glioma susceptibility)[1]No widely established FDA-approved companion biomarker

Beyond the preview

Go deeper on Ephrin type-B receptor 1 (EPHB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ephrin type-B receptor 1 (EPHB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call